Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts have?
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts has 94 citations in the OpenAlex counts ScholarIQ stores.
When was Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts published?
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts has 2013 year in the ScholarIQ index.
What is the open-access status of Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts?
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts has gold oa status in the ScholarIQ index.
What is the DOI of Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts?
The DOI for Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts is on the source record.
What is the PMID of Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts?
The PMID for Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts is on the source record.
What is the OpenAlex record for Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts?
The OpenAlex for Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts is on the source record.